Current - 4 hours ago
Grey lines are ignored Blue lines are triggers
|
Menu
* Discover
* Portfolio
* Team
* Careers
* Login Portal
~ Our portfolio
Our portfolio companies embody the Atlas culture of collaborative, science-first, patient-centric drug development
*
*
*
+ All
+ Active
+ Exited
Seeded
Incubated
Co-founded
Next-generation gene therapies by enabling delivery of large genes
Visit Site
Targeting RNA-modifying proteins for novel precision cancer therapies
Visit Site Careers
Small molecule therapies for severe cardiovascular diseases
SWX: ATLN (2000)
Visit Site
Novel biologic drugs platform
Sold to BMS (2007)
Advancing novel therapies for people with rare cardiopulmonary disease
NASDAQ: AVTE (2021)
Visit Site Careers
Building the future of gene therapy
Visit Site Careers
Reimagining treatments for patients with respiratory illnesses and inflammatory conditions
Sold to GSK (2024)
Restoring metabolic balance to treat NASH and serious metabolic diseases
NASDAQ: AKRO (2019)
Visit Site Careers
RNAi-based drugs for severe diseases
NASDAQ: ALNY (2004)
Visit Site Careers
Novel anesthetics
Sold to The Medicines Company (2015)
Targeting progranulin and lysosomal biology to treat neurodegenerative diseases
Visit Site Careers
Novel cancer drugs using combinatorial chemistry
NASDAQ: ARQL (1996)
Visit Site
Migraine prevention therapy
Sold to Eli Lilly (2013)
Covalent irreversible inhibitors
Sold to Celgene (2012)
Cell and gene therapies for rare diseases
NASDAQ: AVRO (2018)
Visit Site Careers
Engineered B cells as medicines
Visit Site Careers
Novel bicyclic peptides (bicycles) and bicycle drug conjugates for cancer
NASDAQ: BCYC (2019)
Visit Site Careers
Breakthrough therapies for neurological & psychiatric conditions
Sold to Novartis (2020)
Harnessing the power of the epigenome to develop precision genomic therapeutics
Visit Site Careers
Precision therapeutics for genetically defined diseases
Visit Site Careers
Our mission is to develop the first treatment targeting a root cause of preeclampsia
Visit Site
Novel antibodies for immuno-oncology
Sold to Novartis (2014)
Novel vaccine platform
Sold to Johnson & Johnson (2010)
Rapidly developing new cancer treatments for people of all ages
NASDAQ: DAWN (2021)
Visit Site Careers
Population genetics for the discovery of novel drug targets
Sold to Amgen (2012)
Visit Site Careers
Novel biologic therapeutics for autoimmune diseases
Sold to Celgene (2017)
Advancing a Ground-Breaking Approach to Agonist Antibody Therapeutics
Visit Site Careers
Preventing axonal degeneration in patients with neurological diseases
Sold to Lilly (2020)
Innovative treatments for hematologic diseases
NASDAQ: IRON (2022)
Visit Site Careers
Pioneering targeted therapies for serious muscle diseases
NASDAQ: DYN (2020)
Visit Site Careers
Functional genomics-based drug discovery
NASDAQ: EXEL (2000)
Visit Site Careers
Novel bispecific antibodies platform
Sold to invoX Pharma (2023)
Visit Site Careers
Scalable, re-dosable, non-viral gene therapy for genetic diseases
NASDAQ: GBIO (2020)
Visit Site Careers
Genomically recoded organism platform for the development of protein therapeutics
Visit Site Careers
Mouse platforms for the generation of fully human antibodies
Sold to Harbour BioMed (2016)
Therapies for rare and inflammatory diseases
NASDAQ: HZNP (2011)
Visit Site Careers
Unlocking nature's regulatory mechanisms to fuel the discovery of new medicines
Visit Site Careers
Targeting the innate immune system to treat cancer and inflammatory diseases
Sold to BMS (2017); Novartis (2019)
Visit Site Careers
Targeted oncology therapies
NASDAQ: IKNA (2021)
Visit Site Careers
Gene editing therapies
NASDAQ: NTLA (2016)
Visit Site Careers
Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics
Visit Site
Advancing next-generation therapies for obesity and related conditions
Visit Site Careers
Novel therapeutics for severe respiratory diseases
Visit Site
mRNA editing based therapies
Visit Site Careers
Delivering novel small molecule protein degrader medicines
Nasdaq: KYMR (2020)
Visit Site Careers
Among the first to leverage ADC success to develop treatments for autoimmune and inflammatory disorders
Visit Site
Novel therapies for severe neurodegenerative diseases
Sold to Bial in 2020
Treating cancer's toughest tumors through innovation in precision radiopharmaceuticals
Sold to Novartis (2024)
Visit Site Careers
Discovering precision covalent medicines for immune diseases
Visit Site Careers
Novel biologics for cancer treatment
Sold to Amgen (2012)
Development of complex biosimilar products
NASDAQ: MNTA (2004)
Novel antibody discovery platform
XETRA: MOR.DE (1999)
Visit Site Careers
Breakthrough computer-aided drug design for transformative medicines
Visit Site Careers
Novel antibiotics
Sold to AstraZeneca (2010)
Programmable, non-viral platforms for in-vivo delivery of next-generation genetic medicines
Visit Site Careers
New class of regulated cell and gene therapies
Visit Site Careers
Novel medicines for auto-immune diseases
Sold to BMS (2016)
ADC specialist for solid cancers
Visit Site Careers
Targeting regulators of innate and adaptive immunity to restore immune homeostasis
Visit Site Careers
Restoring ABC transporter function for patients with serious genetic diseases
Visit Site Careers
Reprogramming RNA to address undruggable drivers of disease
Visit Site Careers
Next-generation oncolytic immuno-therapies for cancer treatment
NASDAQ: REPL (2018)
Visit Site Careers
Enhancing synaptic integrity for treatment of neurological disorders
Sold to Alkermes (2019)
Targeted oncology therapies
Visit Site Careers
Developing highly effective and differentiated treatments for cystic fibrosis
Visit Site Careers
Novel antibiotics for drug-resistant bacterial infections
NASDAQ: SPRO (2017)
Visit Site Careers
Novel fibrosis therapeutic
Sold to Biogen Idec (2012)
Novel antibodies built to break through the tumor microenvironment
Sold to Coherus (2023)
Visit Site
Pioneering transformative new biotherapeutics for patients
NASDAQ: SYBX (2017)
Visit Site Careers
Advancing medicines for allergy and inflammation
NASDAQ: THRD (2022)
Visit Site Careers
mRNA vaccines and therapies
Sold to Sanofi (2021)
Target-first, rational molecular glue drug discovery platform
Visit Site Careers
Novel antibodies for the treatment of I&I disorders
Visit Site
Next-generation ocular gene therapies for vision restoration and preservation
Sold to Novartis (2020)
Transformative treatments for people with obesity and other cardiometabolic diseases
Sold to Lilly (2023)
Harnessing the power of microglia to transform treatments for neuro-degenerative diseases
NASDAQ: VIGL (2022)
Visit Site Careers
Novel therapeutics using proprietary computational chemistry
Sold to Allergan (2016)
Harnessing the immune system to defeat cancer with tumor-selective immunotherapies
NASDAQ: XLO (2021)
Visit Site Careers
We build breakthrough biotechnology companies
* LinkedIn
* Twitter
* LifeSciVC
* News archive
© 2024 ATLAS VENTURE, All Rights Reserved. Site by Show + Tell
* Contact
* Privacy Policy
|
For now, Differences are performed on text, not graphically, only the latest screenshot is available.
Screenshot requires Playwright/WebDriver enabled